on ABIVAX (EPA:ABVX)
Abivax Reports Outcomes of Annual General Meeting
Abivax, a biotechnology firm based in Paris, announced the results of its annual general meeting held on May 11, 2026. Chaired by Sylvie Grégoire, Chair of the Board, the meeting saw shareholders approving all proposed resolutions. These resolutions included the adoption of the financial statements for 2025 and the compensation policy for key executives.
Furthermore, the Board received approval for delegations concerning upcoming financial transactions. The detailed results of the votes will be accessible on the company's official website. Abivax continues its focus on developing therapies for chronic inflammatory diseases, with its lead candidate, obefazimod, in Phase 3 trials for ulcerative colitis.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news